Diclofenac Topical side effects: what 35,510 FDA adverse event reports show
Drug class
Nonsteroidal anti-inflammatory drug (nsaid)
Label matched
Diclofenac Sodium Topical (Diclofenac Sodium)
Who reports
35,510 reports · 78% serious · 6,889 with death outcome · 74% female
Used for
Diclofenac sodium topical gel is indicated for the topical treatment of actinic keratoses (AK). Diclofenac sodium topical gel is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the topical treatment of actinic keratoses (AK). ( 1 )
What it is
Diclofenac sodium topical gel, 3%, intended for dermatologic use, contains the active ingredient, diclofenac sodium, in a clear, transparent, colorless to slightly yellow or orange gel base. Diclofenac sodium is a white or slightly yellowish hygroscopic crystalline powder.
Boxed warning
RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Thrombotic Events • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.
Causality screen of the 40 strongest signals
What the badges mean
- Labeled — boxed warning The term (or its clinical synonym) appears in the FDA boxed warning: causality is regulator-recognised and considered serious.
- Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,172 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Lupus vulgaris | 840 | 1,458.4 1,285.4–1,654.6ROR 1,493.7 · calibrated p 3e-19 ✓ | 412.6 EB05 389.7 · IC025 +8.3 3/3 methods agree | Not in label — unassessed | serious n=840 · ♀ 100% (drug 74%) · 96% clinician | not reported in cached trials |
| Anti-cyclic citrullinated peptide antibody | 466 | 1,404.3 1,187.8–1,660.3ROR 1,423.0 · calibrated p 6e-19 ✓ | 405.1 EB05 375.2 · IC025 +8.0 3/3 methods agree | Lab value / disease marker | serious n=466 · ♀ 100% (drug 74%) · 96% clinician | not reported in cached trials |
| Swollen joint count increased | 2,042 | 1,145.3 1,063.6–1,233.3ROR 1,215.1 · calibrated p 3e-18 ✓ | 385.0 EB05 371.2 · IC025 +8.4 3/3 methods agree | Lab value / disease marker | serious n=2,041 · ♀ 100% (drug 74%) · 95% clinician | not reported in cached trials |
| Rheumatic fever | 2,767 | 1,041.6 979.6–1,107.6ROR 1,129.6 · calibrated p 6e-18 ✓ | 372.9 EB05 361.4 · IC025 +8.4 3/3 methods agree | Not in label — unassessed | serious n=2,767 · ♀ 100% (drug 74%) · 94% clinician | not reported in cached trials |
| Deep vein thrombosis postoperative | 1,238 | 1,031.6 940.7–1,131.2ROR 1,068.8 · calibrated p 1e-17 ✓ | 370.4 EB05 353.4 · IC025 +8.2 3/3 methods agree | Not in label — unassessed | serious n=1,238 · ♀ 100% (drug 74%) · 93% clinician | not reported in cached trials |
| Hepatic enzyme | 88 | 1,023.6 723.5–1,448.2ROR 1,026.2 · calibrated p 1e-16 ✓ | 343.7 EB05 287.5 · IC025 +6.6 3/3 methods agree | Labeled (related wording) related wording | serious n=88 · ♀ 100% (drug 74%) · 100% clinician | not reported in cached trials |
| Grip strength | 144 | 985.3 753.8–1,288.0ROR 989.3 · calibrated p 9e-17 ✓ | 349.3 EB05 304.0 · IC025 +7.1 3/3 methods agree | Not in label — unassessed | serious n=144 · ♀ 100% (drug 74%) · 100% clinician | not reported in cached trials |
| C-reactive protein | 511 | 772.0 676.6–880.8ROR 783.2 · calibrated p 5e-16 ✓ | 328.2 EB05 305.0 · IC025 +7.8 3/3 methods agree | Lab value / disease marker | serious n=511 · ♀ 100% (drug 74%) · 96% clinician | not reported in cached trials |
| Anti-cyclic citrullinated peptide antibody positive | 3,987 | 765.8 731.3–801.9ROR 862.5 · calibrated p 1e-16 ✓ | 330.6 EB05 322.1 · IC025 +8.3 3/3 methods agree | Lab value / disease marker | serious PRR 244.3 · ♀ 100% (drug 74%) · 93% clinician | not reported in cached trials |
| Facet joint syndrome | 1,628 | 638.1 595.2–684.0ROR 668.7 · calibrated p 3e-15 ✓ | 303.7 EB05 291.5 · IC025 +8.0 3/3 methods agree | Not in label — unassessed | serious n=1,628 · ♀ 100% (drug 74%) · 95% clinician | not reported in cached trials |
| Duodenal ulcer perforation | 3,741 | 620.8 593.5–649.3ROR 693.7 · calibrated p 2e-15 ✓ | 300.3 EB05 292.3 · IC025 +8.1 3/3 methods agree | Labeled — boxed warning synonym match | serious PRR 221.0 · ♀ 100% (drug 74%) · 93% clinician | not reported in cached trials |
| Rheumatoid factor positive | 2,910 | 607.7 577.6–639.5ROR 661.9 · calibrated p 3e-15 ✓ | 297.1 EB05 288.2 · IC025 +8.1 3/3 methods agree | Lab value / disease marker | serious n=2,909 · ♀ 100% (drug 74%) · 94% clinician | not reported in cached trials |
| Swollen joint count | 121 | 576.8 448.7–741.6ROR 578.8 · calibrated p 3e-14 ✓ | 277.4 EB05 238.3 · IC025 +6.7 3/3 methods agree | Not in label — unassessed | serious n=121 · ♀ 100% (drug 74%) · 100% clinician | not reported in cached trials |
| Adjustment disorder with depressed mood | 942 | 522.8 479.0–570.5ROR 537.0 · calibrated p 3e-14 ✓ | 274.3 EB05 259.9 · IC025 +7.8 3/3 methods agree | Not in label — unassessed | serious n=942 · ♀ 100% (drug 74%) · 96% clinician | not reported in cached trials |
| Pemphigus | 5,732 | 509.9 492.9–527.5ROR 607.9 · calibrated p 7e-15 ✓ | 271.9 EB05 266.1 · IC025 +8.0 3/3 methods agree | Not in label — unassessed | serious PRR 200.8 · ♀ 100% (drug 74%) · 93% clinician | not reported in cached trials |
| Hypocholesterolaemia | 139 | 490.0 391.1–613.8ROR 491.9 · calibrated p 1e-13 ✓ | 257.0 EB05 223.1 · IC025 +6.8 3/3 methods agree | Not in label — unassessed | serious n=139 · ♀ 100% (drug 74%) · 100% clinician | not reported in cached trials |
| Retinitis | 718 | 449.0 407.6–494.7ROR 458.3 · calibrated p 2e-13 ✓ | 252.1 EB05 237.0 · IC025 +7.6 3/3 methods agree | Not in label — unassessed | serious n=718 · ♀ 100% (drug 74%) · 96% clinician | not reported in cached trials |
| Dislocation of vertebra | 944 | 438.5 403.3–476.9ROR 450.5 · calibrated p 2e-13 ✓ | 249.2 EB05 236.1 · IC025 +7.7 3/3 methods agree | Not in label — unassessed | serious n=944 · ♀ 100% (drug 74%) · 95% clinician | not reported in cached trials |
| X-ray abnormal | 729 | 410.5 373.5–451.0ROR 419.0 · calibrated p 4e-13 ✓ | 239.5 EB05 225.3 · IC025 +7.6 3/3 methods agree | Lab value / disease marker | serious n=729 · ♀ 100% (drug 74%) · 96% clinician | not reported in cached trials |
| Hand deformity | 5,238 | 396.9 383.8–410.5ROR 465.4 · calibrated p 1e-13 ✓ | 236.1 EB05 230.8 · IC025 +7.8 3/3 methods agree | Not in label — unassessed | serious PRR 189.0 · ♀ 100% (drug 74%) · 93% clinician | not reported in cached trials |
| Helicobacter infection | 3,696 | 337.7 324.7–351.2ROR 376.8 · calibrated p 1e-12 ✓ | 213.8 EB05 208.0 · IC025 +7.6 3/3 methods agree | Not in label — unassessed | serious PRR 166.3 · ♀ 100% (drug 74%) · 93% clinician | not reported in cached trials |
| Sleep disorder due to general medical condition, hypersomnia type | 34 | 304.2 201.0–460.6ROR 304.5 · calibrated p 5e-11 ✓ | 180.0 EB05 134.7 · IC025 +5.1 3/3 methods agree | Not in label — unassessed | serious n=34 · ♀ 100% (drug 74%) · 100% clinician | not reported in cached trials |
| Subcutaneous drug absorption impaired | 175 | 280.4 234.2–335.7ROR 281.8 · calibrated p 2e-11 ✓ | 185.7 EB05 163.7 · IC025 +6.7 3/3 methods agree | Labeled (related wording) related wording | serious n=175 · ♀ 100% (drug 74%) · 96% clinician | not reported in cached trials |
| Muscle injury | 2,608 | 276.1 263.9–289.0ROR 297.9 · calibrated p 1e-11 ✓ | 187.3 EB05 181.4 · IC025 +7.4 3/3 methods agree | Not in label — unassessed | serious PRR 149.4 · ♀ 100% (drug 74%) · 95% clinician | not reported in cached trials |
| Peripheral venous disease | 1,265 | 274.8 257.3–293.6ROR 285.0 · calibrated p 2e-11 ✓ | 186.4 EB05 178.0 · IC025 +7.4 3/3 methods agree | Not in label — unassessed | serious n=1,263 · ♀ 100% (drug 74%) · 94% clinician | not reported in cached trials |
| Seronegative arthritis | 353 | 271.9 239.8–308.4ROR 274.7 · calibrated p 3e-11 ✓ | 183.8 EB05 168.2 · IC025 +7.0 3/3 methods agree | Not in label — unassessed | serious n=353 · 95% clinician | not reported in cached trials |
| Folliculitis | 3,101 | 254.2 244.1–264.9ROR 278.5 · calibrated p 2e-11 ✓ | 177.0 EB05 171.9 · IC025 +7.4 3/3 methods agree | Not in label — unassessed | serious PRR 153.2 · ♀ 100% (drug 74%) · 95% clinician | not reported in cached trials |
| Sleep disorder due to general medical condition, insomnia type | 1,762 | 223.1 211.4–235.5ROR 234.7 · calibrated p 9e-11 ✓ | 161.3 EB05 155.0 · IC025 +7.2 3/3 methods agree | Labeled (related wording) related wording | serious n=1,762 · ♀ 100% (drug 74%) · 95% clinician | not reported in cached trials |
| Pericarditis | 4,482 | 217.9 210.9–225.1ROR 249.2 · calibrated p 5e-11 ✓ | 158.7 EB05 154.8 · IC025 +7.2 3/3 methods agree | Not in label — unassessed | serious PRR 117.8 · ♀ 100% (drug 74%) · 93% clinician | not reported in cached trials |
| Glossodynia (burning tongue/mouth pain) | 5,736 | 204.3 198.6–210.2ROR 243.5 · calibrated p 7e-11 ✓ | 151.4 EB05 148.1 · IC025 +7.2 3/3 methods agree | Labeled (related wording) related wording | serious PRR 161.2 · ♀ 100% (drug 74%) · 93% clinician | not reported in cached trials |
| Synovitis | 4,593 | 202.1 195.7–208.6ROR 232.0 · calibrated p 1e-10 ✓ | 150.1 EB05 146.5 · IC025 +7.2 3/3 methods agree | Not in label — unassessed | serious PRR 115.6 · ♀ 99% (drug 74%) · 93% clinician | not reported in cached trials |
| C-reactive protein abnormal | 1,600 | 197.0 186.3–208.3ROR 206.2 · calibrated p 3e-10 ✓ | 147.1 EB05 141.2 · IC025 +7.1 3/3 methods agree | Lab value / disease marker | serious n=1,600 · ♀ 100% (drug 74%) · 94% clinician | not reported in cached trials |
| Porphyria acute | 320 | 178.4 157.5–202.2ROR 180.1 · calibrated p 1e-9 ✓ | 135.7 EB05 123.7 · IC025 +6.6 3/3 methods agree | Not in label — unassessed | serious n=320 · ♀ 100% (drug 74%) · 94% clinician | not reported in cached trials |
| Inspiratory capacity decreased | 62 | 171.7 129.4–227.9ROR 172.0 · calibrated p 3e-9 ✓ | 127.7 EB05 103.1 · IC025 +5.6 3/3 methods agree | Not in label — unassessed | serious n=62 · ♀ 0% (drug 74%) · 100% clinician | not reported in cached trials |
| Lymphatic fistula | 22 | 166.2 103.5–266.9ROR 166.3 · calibrated p 1e-8 ✓ | 116.6 EB05 81.2 · IC025 +4.4 3/3 methods agree | Not in label — unassessed | serious n=22 · 100% clinician | not reported in cached trials |
| Breast cancer stage iii | 1,348 | 156.7 147.7–166.3ROR 162.9 · calibrated p 2e-9 ✓ | 123.4 EB05 118.0 · IC025 +6.8 3/3 methods agree | Not in label — unassessed | serious n=1,348 · ♀ 100% (drug 74%) · 94% clinician | not reported in cached trials |
| Bone erosion | 689 | 142.7 131.4–155.0ROR 145.5 · calibrated p 6e-9 ✓ | 114.4 EB05 107.4 · IC025 +6.6 3/3 methods agree | Not in label — unassessed | serious n=688 · ♀ 100% (drug 74%) · 97% clinician | not reported in cached trials |
| Lip dry | 1,679 | 136.3 129.4–143.6ROR 143.0 · calibrated p 7e-9 ✓ | 110.5 EB05 106.1 · IC025 +6.7 3/3 methods agree | Not in label — unassessed | serious n=1,675 · ♀ 100% (drug 74%) · 95% clinician | not reported in cached trials |
| Wound | 5,149 | 134.4 130.6–138.2ROR 157.0 · calibrated p 3e-9 ✓ | 109.3 EB05 106.8 · IC025 +6.7 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 106.2 · serious PRR 95.6 · ♀ 100% (drug 74%) · 93% clinician | not reported in cached trials |
| Grip strength decreased | 1,559 | 128.1 121.4–135.2ROR 134.0 · calibrated p 1e-8 ✓ | 105.1 EB05 100.8 · IC025 +6.6 3/3 methods agree | Not in label — unassessed | serious n=1,553 · ♀ 99% (drug 74%) · 94% clinician | not reported in cached trials |
Clinical concept groups
MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.
| Concept | Reports | PRR 95% CI | Reading |
|---|---|---|---|
| Liver injury | 6,820 | 13.613.3–13.9 | signal |
| Interstitial lung disease | 1,526 | 9.59.1–10.0 | signal |
| Hyperglycaemia / diabetes | 3,522 | 6.15.9–6.3 | signal |
| Serious infection | 5,404 | 4.24.1–4.3 | signal |
| Depression | 1,940 | 4.13.9–4.3 | signal |
| Gi bleeding | 1,143 | 3.73.5–3.9 | signal |
| Pancreatitis | 377 | 2.82.5–3.1 | signal |
| Anaphylaxis / angioedema | 578 | 2.72.5–3.0 | signal |
| Rhabdomyolysis / myopathy | 328 | 2.42.1–2.7 | signal |
| Fall / fracture | 1,403 | 2.22.1–2.3 | signal |
| Thrombocytopenia | 773 | 2.11.9–2.2 | raised |
| Severe cutaneous reaction | 233 | 1.91.6–2.1 | raised |
| Tendon disorder | 117 | 1.81.5–2.2 | raised |
| Kidney injury | 1,316 | 1.71.6–1.8 | raised |
| Hyponatraemia | 224 | 1.61.4–1.9 | raised |
| Anaemia | 788 | 1.61.4–1.7 | raised |
Trial evidence (ClinicalTrials.gov)
✓ Trial adverse-event data found on ClinicalTrials.gov
Largest completed trials with posted results that list Diclofenac Topical as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (0 of 40 signal terms matched).
- NCT03172780 — A Bioequivalence Study Using Clinical Endpoint for Diclofenac Sodium Gel 1% in Osteoarthritis Knee" (N=1220, PHASE3; 4 AE terms posted; arms: Diclofenac Sodium Gel; Voltaren® Gel; Placebo Gel)
- NCT02121002 — Study Comparing a Generic Diclofenac Sodium Topical Gel, 1% to Voltaren in the Treatment of Subjects With Oste (N=1176, PHASE3; 6 AE terms posted; arms: Diclofenac Sodium Topical Gel, 1%; Voltaren Topical Gel, 1%; Vehicle Diclofenac Sodium Topical Gel)
Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Drug ineffective (drug did not work) | 7,706 | 3.5 3.4–3.5ROR 4.2 · calibrated p 0.350 | 3.5 EB05 3.4 · IC025 +1.8 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 3.5 · serious PRR 5.9 | not reported in cached trials |
| Pain | 7,444 | 7.2 7.1–7.4ROR 8.9 · calibrated p 0.048 ✓ | 7.1 EB05 7.0 · IC025 +2.8 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 6.3 · serious PRR 8.0 | not reported in cached trials |
| Fatigue (tiredness) | 7,025 | 5.4 5.3–5.5ROR 6.5 · calibrated p 0.123 | 5.3 EB05 5.2 · IC025 +2.4 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 4.4 · serious PRR 7.2 · ♀ 94% (drug 74%) | not reported in cached trials |
| Rheumatoid arthritis | 6,411 | 35.5 34.6–36.3ROR 43.0 · calibrated p 3e-5 ✓ | 33.5 EB05 32.8 · IC025 +5.0 3/3 methods agree | Not in label — unassessed | age-adj. PRR 27.0 · serious PRR 30.0 · ♀ 99% (drug 74%) · 91% clinician | not reported in cached trials |
| Rash | 6,128 | 8.5 8.3–8.6ROR 10.0 · calibrated p 0.032 ✓ | 8.3 EB05 8.2 · IC025 +3.0 3/3 methods agree | Labeled — boxed warning exact term | age-adj. PRR 7.4 · serious PRR 13.2 · ♀ 96% (drug 74%) | NCT02121002: 1/391 (0.3%) on Diclofenac Topical |
| Abdominal discomfort | 6,034 | 22.1 21.6–22.6ROR 26.4 · calibrated p 5e-4 ✓ | 21.3 EB05 20.9 · IC025 +4.4 3/3 methods agree | Not in label — unassessed | age-adj. PRR 17.7 · serious PRR 34.7 · ♀ 99% (drug 74%) | not reported in cached trials |
| Systemic lupus erythematosus | 5,897 | 118.2 115.2–121.3ROR 141.5 · calibrated p 7e-9 ✓ | 98.4 EB05 96.3 · IC025 +6.6 3/3 methods agree | Not in label — unassessed | age-adj. PRR 102.3 · serious PRR 74.3 · ♀ 100% (drug 74%) · 93% clinician | not reported in cached trials |
| Alopecia (hair loss) | 5,794 | 17.9 17.5–18.3ROR 21.2 · calibrated p 0.002 ✓ | 17.4 EB05 17.0 · IC025 +4.1 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 14.2 · serious PRR 27.1 · ♀ 100% (drug 74%) · 91% clinician | not reported in cached trials |
| Off label use (used outside approved label) | 5,763 | 3.9 3.8–4.0ROR 4.5 · calibrated p 0.295 | 3.9 EB05 3.8 · IC025 +1.9 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 3.8 · serious PRR 4.9 | not reported in cached trials |
| Glossodynia (burning tongue/mouth pain) | 5,736 | 204.3 198.6–210.2ROR 243.5 · calibrated p 7e-11 ✓ | 151.4 EB05 148.1 · IC025 +7.2 3/3 methods agree | Labeled (related wording) related wording | serious PRR 161.2 · ♀ 100% (drug 74%) · 93% clinician | not reported in cached trials |
| Pemphigus | 5,732 | 509.9 492.9–527.5ROR 607.9 · calibrated p 7e-15 ✓ | 271.9 EB05 266.1 · IC025 +8.0 3/3 methods agree | Not in label — unassessed | serious PRR 200.8 · ♀ 100% (drug 74%) · 93% clinician | not reported in cached trials |
| Swelling | 5,450 | 36.6 35.6–37.5ROR 43.0 · calibrated p 3e-5 ✓ | 34.5 EB05 33.7 · IC025 +5.1 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 29.4 · serious PRR 40.8 · ♀ 98% (drug 74%) · 92% clinician | not reported in cached trials |
| Arthropathy | 5,261 | 61.5 59.9–63.1ROR 72.0 · calibrated p 1e-6 ✓ | 55.7 EB05 54.4 · IC025 +5.7 3/3 methods agree | Not in label — unassessed | age-adj. PRR 48.0 · serious PRR 49.8 · ♀ 99% (drug 74%) · 92% clinician | not reported in cached trials |
| Joint swelling | 5,253 | 26.9 26.2–27.6ROR 31.4 · calibrated p 2e-4 ✓ | 25.7 EB05 25.2 · IC025 +4.6 3/3 methods agree | Not in label — unassessed | age-adj. PRR 22.3 · serious PRR 32.3 · ♀ 96% (drug 74%) · 91% clinician | not reported in cached trials |
| Hand deformity | 5,238 | 396.9 383.8–410.5ROR 465.4 · calibrated p 1e-13 ✓ | 236.1 EB05 230.8 · IC025 +7.8 3/3 methods agree | Not in label — unassessed | serious PRR 189.0 · ♀ 100% (drug 74%) · 93% clinician | not reported in cached trials |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Lupus vulgaris — n=840, PRR 1,458.4
- Rheumatic fever — n=2,767, PRR 1,041.6
- Deep vein thrombosis postoperative — n=1,238, PRR 1,031.6
- Grip strength — n=144, PRR 985.3
- Facet joint syndrome — n=1,628, PRR 638.1
- Swollen joint count — n=121, PRR 576.8
- Adjustment disorder with depressed mood — n=942, PRR 522.8
- Pemphigus — n=5,732, PRR 509.9
- Hypocholesterolaemia — n=139, PRR 490.0
- Retinitis — n=718, PRR 449.0
✓ A hand-written Bradford Hill causality assessment exists for this drug: Methotrexate Sodium ↔ Rheumatoid Arthritis.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Diclofenac Topical?
In FDA FAERS, the most frequently co-reported reaction terms for Diclofenac Topical are pain, fatigue, rheumatoid arthritis, rash, abdominal discomfort, systemic lupus erythematosus. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Diclofenac Topical have an FDA boxed warning?
Yes. The current FDA label carries a boxed warning: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Thrombotic Events • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.
Do FAERS signals prove that Diclofenac Topical causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 140a2c64-4996-4da3-b10f-1b8235ebde9d, effective 20251201; matched on
openfda.generic_name.exact:"DICLOFENAC SODIUM TOPICAL") - Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,212 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
DICLOFENAC TOPICAL, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.